NANSAIDNon-Aspirin Non-Steroidal Anti-Inflammatory Drugs
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
Recent reports suggest a reduced risk of Alzheimer's disease in people who take NANSAIDs. This was first shown in studies of twin-pairs, with a lower rate of Alzheimer's disease in those exposed to anti-inflammatory agents [44].
The mechanism of action of NANSAIDs and aspirin is mediated by inhibition of prostaglandin synthesis through an interaction with the enzyme cyclo-oxygenase.
Benefits include a reduction in thrombo-embolic stroke--although with a possible increase of haemorrhagic stroke [33, 37]--and a reduction in myocardial infarction rates with NANSAIDs (although this has yet to be confirmed in a prospective study).
The use of NANSAIDs with minimal COX-1 inhibition may not require upper gastrointestinal prophylaxis, and may have a lower incidence of adverse gastrointestinal effects.